Kazia dropped from global umbrella trial to treat brain cancer – FierceBiotech

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The basket case February 10, 2021 # # # # One of the more interesting pieces of clinical trial news in 2020 was the publication of the results of a “basket study” for neurological conditions. This was a trial that involved a drug being tested on a selection of neurodegenerative conditions, rather than just one condition. Between December 2013 to May 2017, researchers recruited a total…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• A plutocratic proposal: iCancer February 2, 2020    Speeding up the clinical development process is a shared goal across many medical conditions (not just Parkinson’s and neurodegeneration), and there are many different approaches to achieving this that are being explored. Some of these approaches could be considered to be bordering on the unethical, but there are aspects of their structure and design that are still worthy of…
• EJS-ACT PD June 26, 2021 # # # # This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted. The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for evaluating new therapies for PD.…
• Parkinson’s Disease & Risk of Cancer February 12, 2019 Parkinson’s disease and cancer: what’s the connection? Researchers have long tried to understand the relationship between Parkinson’s disease (PD) and cancer, with multiple studies conducted over the years. Intuitively, PD and cancer are not at all similar, and can even be thought of as biochemically opposite – in one disease (PD), cells die unexpectedly and in the other (cancer), cells…
• Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews. January 14, 2021 Related ArticlesNon-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews. BMC Med. 2021 Jan 13;19(1):6 Authors: Mentis AA, Dardiotis E, Efthymiou V, Chrousos GP Abstract BACKGROUND: The etiologies of chronic neurological diseases, which heavily contribute to global disease burden, remain far from elucidated. Despite available umbrella reviews on single contributing factors or…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• Parkinson’s Awareness Month is a time to look outward, not inward March 30, 2019 Who decides which disease or cause can lay claim to a month as an awareness month? I’m just curious, because we’re about to enter April, which for some reason is Parkinson’s Disease Awareness Month. It's not that I don't believe that PD deserves an awareness month. My issue is that I feel like a hypocrite. I am so aware of…
• Monthly Research Review – December 2021 December 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Carbidopa Reduced Tumor Growth in Lab Studies of Cancer October 6, 2017 Carbidopa, a medicine approved for the treatment of Parkinson’s disease, also has shown anti-cancer effects in lab-grown human cells and mice, according to the results of a new study. The findings help explain why cancer incidence usually is lower in Parkinson’s patients — with the exception of skin cancer — and suggest that carbidopa may be explored further as an anticancer…
• Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Effectiveness of non-pharmacological falls prevention interventions for people with Multiple Sclerosis, Parkinson's Disease and stroke: protocol for an umbrella review. January 5, 2021 Related ArticlesEffectiveness of non-pharmacological falls prevention interventions for people with Multiple Sclerosis, Parkinson's Disease and stroke: protocol for an umbrella review. HRB Open Res. 2020;3:17 Authors: O'Malley N, Clifford AM, Comber L, Coote S Abstract Background: Falls are common among people with neurological diseases and are associated with many negative physical, psychosocial and economic consequences. Implementation of single diagnosis falls…
• The Bluerockers have started July 15, 2021 # # # # On the 8th June, BlueRock Therapeutics put out a press release announcing that the first participant in their Phase I clinical trial of cell transplantation for Parkinson’s had been dosed (Click here to read the press release). The initiation of this clinical trial by the company is a major step forward for them and for the…
• Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds August 22, 2019 A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at no increased risk of prostate cancer. As such, the agency stands by its current recommendations for the use of Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone; brand name is Comtess elsewhere) to ease motor problems in Parkinson’s disease. The FDA review was conducted after the findings…
• Monthly research review – March 2022 March 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• A rising tide with liraglutide April 18, 2022 # # # # A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of Parkinson’s. Recently, the results of…
• Does immunotherapy need therapy? June 12, 2021 # # # # Over the last decade, a large number of clinical trials involving immunotherapy have been conducted in the field of Alzheimer’s research. The overall success rate of these studies has not been encouraging. Immunotherapy involves artificially boosting the immune system so that it targets of particular pathogen – like a rogue protein in the case of Alzheimer’s…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…